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AbstrAct  A life course approach in epidemiology investigates the biological, behavioral 
and social pathways that link physical and social exposures and experiences during gestation, 
childhood, adolescence and adult life, and across generations, to later-life health and disease 
risk. We illustrate how a life course approach has been applied to cardiovascular disease, 
highlighting the evidence in support of the early origins of disease risk. We summarize how 
trajectories of cardiometabolic risk factors change over the life course and suggest that 
understanding underlying ‘normal’ or ‘healthy’ trajectories and the characteristics that drive 
deviations from such trajectories offer the potential for early prevention and for identifying 
means of preventing future disease.
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Coronary heart disease (CHD) and stroke are rare until middle age, but the pathophysiological 
process of atherosclerosis, which ultimately leads to cardiovascular disease (CVD), is initiated in 
early life. Fatty streaks and clinically significant raised lesions have been observed in autopsy stud-
ies of 15–19-year-old individuals [1] and fatty streaks have even been found to occur in the aorta 
of premature fetuses, particularly among those of mothers with hypercholesterolemia during preg-
nancy [2]. Hence, it is important to understand the factors from across life that may influence the 
development and progression of the disease process. Recent guidelines have emphasized evidence 
that long-term and cumulative exposure to modifiable risk factors from an early age advances the 
disease process. The calculation of lifetime as well as short-term (10-year) risk of CVD, particularly 
for men and women in midlife with a low short-term risk, has been recommended by the American 
College of Cardiology/American Heart Association [3] and the Joint British Societies [4], while the 
International Atherosclerosis Society recommends risk assessment be based on lifetime risk in the 
management of dyslipidemia [5]. A life course approach to cardiovascular (CV) health is further 
promoted by the American Heart Association, who have provided metrics for children and adults in 
relation to health behaviors (smoking, physical activity, diet and BMI) and health factors (diabetes, 
total cholesterol and blood pressure [BP]) [6]. We suggest that life course epidemiological research 
has shown that all these CV metrics have their origins in early life through a multiplicity of path-
ways, and here provide some evidence relating to cardiometabolic function (specifically BP, lipid 
profiles and markers of diabetes, such as glucose and insulin); the early origins of health behaviors 
are reviewed elsewhere [7,8].
To date, there is a greater body of evidence relating preadult influences with cardiometabolic 
measures or disease outcomes at a single time point in adulthood, with less attention paid to the 
factors that drive changes in cardiometabolic function. In this article, after an introduction to life 
course epidemiology, we describe the trajectories of cardiometabolic function across the whole of 
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life. We highlight the evidence linking selected 
life course risk factors to CVD and these car-
diometabolic trajectories, and review evidence 
suggesting that changes in cardiometabolic risk 
factors at particular periods of the life course 
may be associated with disease onset.
Life course epidemiology
A life course approach in epidemiology investi-
gates the biological, behavioral and social path-
ways that link physical and social exposures and 
experiences during gestation, childhood, ado-
lescence and adult life, and across generations, 
to later-life health and disease risk [9,10]. Adult 
chronic disease, particularly cardiometabolic and 
respiratory disease, was the initial focus of life 
course epidemiology, although this approach has 
been extended subsequently to other health out-
comes. The ground-breaking studies of Barker 
and colleagues in the 1980s that linked birth 
weight and other measurements of birth size 
(as proxy markers of growth in utero) to cardio-
metabolic disease in later life [11] were a catalyst 
for the development of life course epidemiology. 
The programming or ‘Barker hypothesis’, which 
states that exposures during critical (or sensi-
tive) developmental periods have long-term con-
sequences for chronic disease, evolved into the 
more general developmental origins of the adult 
disease model that includes the impact of post-
natal as well as prenatal development on health. 
The role of early-life socioeconomic conditions 
has also been widely investigated in relation to 
CVD, and although initially seen as a competing 
model to the fetal programming hypothesis, life 
course epidemiology emphasized the importance 
of both early biological and social factors.
Prior to the re-emergence of life course ideas 
in epidemiology in the 1990s [12], the adult life-
style and risk factor model of health had been 
dominant, as it had been successful in identify-
ing many modifiable causes of disease and in 
particular CVD, such as hypertension and inac-
tivity. Life course epidemiology acknowledges 
the importance of these adult risk factors, but 
it adds a life course perspective by recognizing 
their tracking from childhood to adulthood. In 
terms of health-related behaviors, it emphasized 
the need to understand the predictors of the ini-
tiation and cessation of health-promoting and 
health-damaging behaviors across life. The life 
course perspective thus integrated and extended 
these three apparently conflicting theories of 
disease etiology: fetal programming, social 
causation and adult lifestyle. Life course epi-
demiology attempts to understand the relative 
importance of exposures from across the whole 
of life, their interactions and the underlying 
processes.
The initial concepts of life course epidemiol-
ogy were proposed by Ben-Shlomo and Kuh as 
a theoretical basis for the testing of life course 
hypotheses [10]. Initially, two broad types of life 
course model – a critical period model and an 
accumulation of risk model – were proposed, 
with each type having several submodels (see 
Ben-Shlomo and Kuh [10] for a detailed review). 
The difficulties in practice of empirically teas-
ing out the particular life course models have 
been highlighted [13,14]. More generally, the 
statistical models used for the testing of life-
course hypotheses are complex due to repeated 
and correlated outcome and exposure measures 
and the methods are still developing and evolv-
ing [15,16]. Whatever the statistical approach, an 
understanding of the underlying biology and 
careful consideration of confounding variables 
and other potential biases are required. The 
influence of chance events and processes must 
also be recognized [17]. Such random processes 
mean that any life course model is unable to 
predict individual outcomes and can only pro-
vide information on how the development of risk 
varies across groups.
More recently, life course epidemiology 
has emphasized the importance of age-related 
changes in functional capability, using tests of 
strength and physical performance (e.g., grip 
strength, standing balance and gait speed) and 
cognitive performance [18]. Life course epidemi-
ology is thus interested in modeling develop-
mental trajectories that may provide clues to the 
early-life exposures influencing development, as 
well as the age-related decline in functioning that 
occurs postmaturity [18]. The rate of functional 
decline reflects growing impaired physiologi-
cal responses to environmental and behavioral 
challenges. In relation to CVD, understand-
ing how markers of cardiometabolic function 
change across life and identifying underlying 
‘normal’ or ‘healthy’ trajectories and the factors 
associated with deviation in these trajectories 
are potentially important for understanding the 
development of CVD and for preventing future 
disease [19].
Other recent developments focus on how 
life course epidemiology can go beyond sim-
ply demonstrating associations to determining 103
A life course approach to cardiovascular aging  review
future science group www.futuremedicine.com
whether associations are causal. Replication of 
results in several cohort studies, in particular 
in studies from populations with contrasting 
confounding structures, increases confidence 
that the observed associations may be causal. 
Another approach is the use of instrumental 
variables, with genetic instrumental variables 
being most commonly used to date, with the 
technique being termed ‘Mendelian randomi-
zation’ [20]. Because the genetic instrumental 
variable is related to the outcome only through 
the exposure and is unrelated to any confound-
ers of exposure and outcome, the relationships 
between instrument and outcome and between 
instrument and exposure can be used to derive 
an unconfounded estimate of the causal effect 
of exposure on outcome.
Life course trajectories of cardiometabolic 
function
Longitudinal studies in which repeated meas-
ures of a cardiometabolic risk factor are recorded 
from the same individuals over time are required 
to investigate true within-individual age-related 
change. Trajectories inferred from cross-sec-
tional studies can be influenced by secular or 
birth cohort differences. Of all the cardiometa-
bolic risk factors, life time trajectories in BP have 
been by far the most extensively studied [19].
● ● Life course trajectories of BP
There is still no single study with BP measured 
in the same individuals across the whole of life. 
Hence, an alternative to examining life course 
trajectories in a single cohort, and an improve-
ment over cross-sectional analyses of individuals 
of different ages, is to compare multiple longi-
tudinal cohorts with repeated measurements 
that cover different periods of life. One study 
modeled systolic BP (SBP) data from seven UK 
prospective cohort studies, each with at least two 
measurements of BP and each covering different 
but overlapping periods of the life course from 7 
to >80 years of age [21]. Four life course phases 
were observed: a rapid increase in SBP coincid-
ing with peak adolescent growth; a more gentle 
increase in early adulthood; a midlife accel-
eration beginning in the fourth decade; and a 
deceleration in late adulthood in which increases 
in SBP slowed and at very old age appeared to 
decline. A greater increase in SBP in boys com-
pared with girls was observed in childhood, 
and by the mid-20s, SBP was markedly higher 
in men compared with women. By contrast, a 
greater midlife increase was observed in women 
compared with men, so that by approximately 
60 years of age, mean SBP was higher in women. 
Other cross-sectional and longitudinal stud-
ies generally support these findings, with SBP 
increasing monotonically across most of adult 
life. Diastolic BP (DBP) has been observed to 
increase to the fifth decade, and thereafter to pla-
teau or decline [22,23]. The midlife rate of increase 
in DBP, similarly to that of SBP, is greater in 
women compared with men, but is not as steep 
as that for SBP [23].
Project HeartBeat! is a detailed study of BP in 
childhood [24] in which BP was assessed repeat-
edly every 4 months for 4 years in approximately 
700 children initially aged 8, 11 or 14 years. 
Mean levels of SBP increased steeply between 
ages 8 and 16 years and then leveled off, with the 
rate of increase being greater in males compared 
with females. There were no clear ethnic differ-
ences. For phase 4 DBP, there was a curvilinear 
association, with the rate of increase reducing 
after approximately 13 years, whereas the rate of 
age-related increases for phase 5 was more con-
stant. Mean phase 4 DBP was higher in males 
than females at all ages, and both measures of 
DBP were higher in black children at all ages. 
However, rates of change were similar in males 
and females and in blacks and non-blacks.
At the other end of life in the seventh and 
eigth decades, the extent to which the slowing of 
the increase, or even decrease, in BP seen in most 
studies is driven by survivor bias (i.e., survival of 
those who are most healthy, with lower BP and 
less prone to premature mortality) or effective 
treatment for lowering BP remains unclear. The 
decline has been less evident in analyses that 
have excluded individuals on antihypertensive 
medication [21], suggesting reduction of BP by 
treatment may play a role. However, age-related 
weight loss, arterial stiffening and changes in 
the autonomic control of BP are possible age-
related processes that could explain a decline 
[25].
There is evidence of considerable variation in 
the extent to which BP rises druing adulthood. 
An occupational cohort (the Whitehall II study) 
had a mean SBP trajectory that did not begin 
the accelerated rise until a later age when com-
pared with the general population cohorts in the 
UK cross-cohort study [21]. A comparative study 
observed little age-related change in BP from the 
four nonindustrialized remote populations that 
were considered, which was in contrast to the Future Cardiol. (2015) 11(1) 104
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substantial increases seen in western populations 
[26]. A recent longitudinal study of adult lowland 
forager horticulturalists from Bolivia found that 
BP did increase with age, particularly among 
women, but that the rate of increase was consid-
erably less than that in the general US population 
[27]. As well as differences between populations, 
there is likely to be considerable variation within 
populations regarding the average trajectories, 
which are not evident when simply modeling 
the means. In a latent class analysis of midlife 
British adults aged 36–53 years, three subgroups 
of BP change were identified [28]. In both men 
and women, and for both SBP and DBP, there 
was a large ‘normal’ group, which included over 
90% of participants and was characterized by 
steady increases. There was also a smaller group 
in which the rate of increase was three- to four-
times greater than that of the large ‘normal’ 
group, and in women, there was a third subgroup 
in whom BP was consistently high. A subsequent 
US study in men and women aged 18–30 years 
at baseline was able to identify a group of indi-
viduals whose BP remained low over the course 
of the study, along with four other groups with 
increasing or relatively high BP [29]. Identifying 
such apparently healthy groups and their char-
actersitics may help to identify novel life course 
interventions. Overall, these findings demon-
strating considerable variation both within and 
between populations provide no clear evidence 
that marked midlife increases in BP are part of a 
natural physiological aging process, but instead 
may suggest that western lifestyles are driving 
the increases.
● ● Life course trajectories of lipids & glucose
Early-life lipid changes vary between boys and 
girls  [30,31]. In a prospective study, levels of 
total cholesterol and LCL-cholesterol (LDL-
C) declined with age from 8 to 16 years, with 
this decline being more rapid in boys than in 
girls in a prospective study, while triglyceride 
levels increased with increasing age more mark-
edly in boys than girls [31]. Patterns of change 
in HDL-cholesterol (HDL-C) were very differ-
ent between girls and boys, with a sinusoidal 
pattern in boys with a peak at approximately 
11 years of age and a trough at approximately 
15 years of age, but little change in levels in girls 
until 15 years of age, when levels increased. No 
ethnic differences in mean levels or change in 
total cholesterol were found, but the mean levels 
of LDL-C, HDL-C and triglycerides at all ages 
were more adverse in non-black compared with 
black children [31].
There are only a few longitudinal studies of 
age-related changes in lipids in adults. In west-
ern industrialized countries, total cholesterol, 
LDL-C and triglycerides increase from early 
adulthood to at least the sixth decade of life, 
and HDL-C declines over this same period 
[32,33]. Total cholesterol, LDL-C and triglycer-
ide levels are greater in men in early adulthood, 
but the slope of increase from the early 30s to 
later life is greater in women than in men, and 
similarly, HDL-C is lower in men in early adult-
hood, but the decline over adulthood is greater 
in women [32,33]. In more recent studies, the 
magnitude of the increase with age was lower, 
which may reflect greater use of statins and/or 
improvements in lifestyle [32]. Data from repeat 
US NHANES cross-sectional surveys suggest 
that mean fasting glucose in males and females 
and all ethnic groups remain constant from age 
12–20 years [34]. Fasting and postload glucose 
levels have been found to increase with age from 
early adulthood to old age, with a suggestion of 
a sharp increase in the rate of increase in glucose 
and insulin from approximately 60 years of age 
[35]. Gender differences appear less marked than 
those seen for SBP and total cholesterol. This 
adult age-related change is probably driven by 
age-related weight gains and declines in physical 
activity [36].
Life course biological transitions
As well as the long-term changes, there are 
also biological transitions in which particularly 
rapid changes in cardiometabolic trajectories 
occur, such as puberty and, in women, dur-
ing pregnancy and the menopause transition. 
Mean trends in risk factors with age may be too 
crude to identify effects of the changes relat-
ing to such events, particularly as they occur at 
different ages in different individuals. Whether 
the patterns of change during such transitions 
are related to subsequent cardiometabolic tra-
jectories and subsequent disease development 
remains unclear, even though the timing of 
such reproductive transitions have long been 
investigated in relation to CV health in women. 
Acknowledging the metabolic changes that 
occur during pregnancy, pregnancy has been 
proposed as a physiological ‘stress test’ that 
reveals latent chronic disease [37], while more 
generally, reproductive health has been sug-
gested as a ‘sentinel of chronic disease’ [38].105
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● ● Puberty
Some, but not all studies show an association 
between earlier age at menarche in girls and sub-
sequent increased CHD risk [39] and worse CV 
risk factors [40–42], but the extent to which this is 
explained by the higher adiposity in adulthood 
and/or the tracking of BMI from childhood 
remains unclear, as few studies have later-life 
measures of body size.
● ● Pregnancy
Detrimental changes to the CHD risk profile, 
including a relative degree of insulin resistance 
and hypertriglyceridemia, which are necessary 
for fetal growth and development, occur dur-
ing pregnancy, but how long they remain after 
delivery is not known. Associations between ear-
lier age at first pregnancy and larger numbers 
of pregnancies with higher rates of CVD may 
be due to confounding by preparenthood fac-
tors and be mediated by health-related behaviors 
rather than the biological effects of pregnancy. 
Studies that have compared the association 
between number of children and CVD and 
CV risk factors in men and women can help 
to disentangle the pathways, but to date, such 
studies are few and their results are not entirely 
consistent [43,44].
In addition to the metabolic changes in a nor-
mal pregnancy, many of the factors that contrib-
ute to CVD, such as inflammation, vasculopa-
thy, angiogenesis, thrombosis, insulin resistance 
and endocrine profiles, also underlie aberrant 
menstrual patterns, female infertility, pregnancy 
complications and adverse pregnancy outcomes 
[38]. In particular, four common pregnancy com-
plications – gestational diabetes, hypertensive 
disorders, low birth weight and preterm birth 
– may reveal CV maternal risks. Women expe-
riencing pre-eclampsia during pregnancy have a 
higher rate of subsequent hypertension [45] and 
CHD and stroke [46] than women who have nor-
motensive pregnancies. Offspring birth weight 
predicts maternal lifespan and CV mortality, 
with lower birth weight being associated with 
increased risk [47], and mothers who deliver a 
preterm baby also have an increased risk of CHD 
[48,49]. The combination of preterm birth, low 
birth weight for gestational age and pre-eclamp-
sia appear to be additive; one study, for example, 
found that women with all three characteristics 
had a risk of CHD admission or death that was 
seven-times greater than for women with none 
of these characteristics [48].
● ● Reproductive aging
Earlier menopause has been associated with 
an increased risk of CHD [50], and as noted 
previously, both SBP and DBP increase more 
in midlife in women than they do in men. 
However, prospective studies that have modeled 
BP as women go through the menopause suggest 
little or no specific effect of the menopause per 
se, over and above that due to aging [51]. By con-
trast, it has been suggested that there was a spe-
cific increase in total cholesterol and LDL-C at 
approximately the final menstrual period, with 
the same level being maintained 6 years later [51]. 
The prevailing view that the estrogen drop dur-
ing the menopausal transition triggers somatic 
aging, probably through detrimental changes to 
risk factor levels, is being challenged. Ovarian 
aging may be a result of somatic aging or under-
lying disease or their common antecedents. A 
study based on the Framingham cohort linked 
premenopausal high BP and poor lipid profile 
with early menopause [52]. This led the authors 
to propose that, rather than being a result of 
menopause or being linked by common factors, 
detrimental changes in CHD risk factors may 
determine age at menopause.
A few studies have shown that women who 
suffer from vasomotor symptoms (hot flashes 
and night sweats) during the menopause have 
an increased risk of subsequent CHD [53], sub-
clinical CVD [54] and a poorer CV risk factor 
profile [55]. The design of many of the existing 
studies, however, again means that it is not pos-
sible to determine whether CHD risk factors and 
vascular changes precede vasomotor symptoms, 
whether symptoms are a marker of underly-
ing vascular changes or whether the two have 
co mmon  antecedents.
Life course risk factors for adult 
cardiometabolic function & CvD: 
examples
We now provide a brief overview of the evidence 
relating the commonly studied life course risk 
factors of prenatal and postnatal body size and 
socioeconomic position (SEP) to CVD devel-
opment. Having summarized the evidence in 
relation to disease end points, we then concen-
trate on the associations of these factors with 
the continuous measures of cardiometabolic risk 
factors, and where possible, highlight research 
on factors influencing the shape of the life course 
trajectories. Other early-life factors, such as diet, 
physical activity and psychological stress, are Future Cardiol. (2015) 11(1) 106
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not reviewed here, but may play a role in CVD 
development, either as independent risk factors 
or mediators of the associations between body 
size or SEP and cardiometabolic function.
● ● Developmental origins of CvD
Since the original work by Barker, multiple stud-
ies have investigated associations between birth 
weight and later-life outcomes, with many being 
the subject of systematic reviews and meta-anal-
yses. One systematic review has shown a consist-
ent association of lower birth weight with increas-
ing rates of CHD [56]. The association between 
birth weight and diabetes may be U-shaped in 
populations with high levels of maternal obesity 
and gestational diabetes [57], and it is possible 
that this may, in future, translate into increases 
in CHD at the high end of birth weight as well. 
A life course approach encouraged investigation 
of whether the associations between early-life 
growth and adult disease were confounded by 
socioeconomic circumstances, as had initially 
been suggested. Generally, it was found that 
there was little evidence of such confounding or 
of consistent modification by later-life factors.
Low birth weight is associated with higher BP 
in adulthood, but only weakly associated with 
adverse lipid profiles in childhood and adult-
hood [58,59]. It has been suggested that the nega-
tive association between birthweight and SBP, 
although initiated in utero, is amplified with 
age [60]. The initial evidence in support of this 
hypothesis came from comparisons of multiple 
studies with BP measured at different ages [60], 
and so the apparent amplification of the asso-
ciation might actually be a result of stronger 
associations in historical compared with more 
contemporary birth cohorts. The suggestion of 
amplification within individuals is equivalent to 
hypothesizing that those of lower birth weight 
have faster increases in BP than others. Studies 
with repeated measures of BP within the same 
sample in adulthood suggest that the association 
between birthweight with BP remains constant 
at all adult ages [61,62], and two studies have 
found no amplification of the effect between 
childhood and early adulthood [63,64], but one 
study suggested an increase in the effect between 
adolescence and early adulthood [65]. These dis-
crepancies could be due to differences in whether 
current body size was adjusted for [66].
Birth weight has been the most commonly 
used, although not the only marker of fetal 
development, primarily because it is widely 
available in historical studies. However, birth 
weight is a combination of gestational age and 
fetal growth rate at different periods of preg-
nancy. Contemporary cohorts that have initi-
ated follow-up in pregnancy have more sophis-
ticated measures; for example, the Southampton 
Women’s Study recorded ultrasound measure-
ments in pregnancy to enable the calculation of 
fetal growth in early, mid and late pregnancy [67], 
but such cohorts are still young. Older cohorts 
do not have adequate variation in gestational age 
to assess the potentially independent effects of 
fetal growth and gestational age, but with more 
premature babies (<37 weeks gestation) surviv-
ing into adulthood in younger cohorts, under-
standing the implications of prematurity on later 
CHD risk is an increasingly important priority. 
Younger gestational age has so far been related to 
higher BP through to midlife [68]. There are also 
increasing numbers of babies being conceived 
through assisted reproductive technolgies (ART) 
and being delivered by cesarean section. A meta-
analysis of 13 studies suggested that children 
delivered by cesarean section had greater odds 
of obesity than those delivered naturally [69], but 
there is as-yet little information regarding the 
relationship with other cardiometabolic factors. 
The fact that babies conceived through ART 
have, on average, lower birth weights and greater 
risks of preterm birth than those conceived natu-
rally suggests that they may be at increased risk 
of subsequent CHD. There is currently some 
evidence suggesting increased BP and vascular 
dysfunction risk in children who were con-
ceived through ART, although more research is 
required to replicate such findings in more recent 
cohorts given the rapid improvement in assisted 
reproduction techniques, as well as to tease out 
the mechanisms that are involved [70].
● ● Childhood & adolescent body size & CvD
A number of aspects of postnatal body size, 
such as infant growth, tempo of height growth, 
pubertal growth and childhood obesity, may be 
important in shaping later CVD risk. Reviews 
of the existing literature suggest that high BMI 
in late childhood/adolescence is associated with 
a higher risk of CHD, but there is less and some-
what conflicting evidence in relation to BMI in 
infancy/early childhood [71–73]. A large Danish 
cohort with repeated measures of BMI found 
that the positive associations between BMI and 
CHD were strengthened with the older age of 
BMI measurement from 7 to 13 years [73]. The 107
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Helsinki Birth Cohort Study observed that those 
who developed CHD were smaller than others in 
infancy, but showed more rapid increases in BMI 
up to 12 years of age [74,75]. Thus, the strength 
and direction of association may change with 
age at BMI measurement. From a public health 
perspective, it is important to establish whether 
becoming normal weight in adult life reverses 
any adverse effects of childhood overweight, but 
few existing studies have been able to adjust for 
adult body size. One study observed only slight 
attenuation of the association of adolescent over-
weight with CHD upon the addition of adult 
BMI, although there were only 38 events and 
thus confidence intervals were wide [76].
Greater adiposity at any time of life is cross-
sectionally associated with higher BP, and 
greater childhood adiposity is associated with 
higher adult BP. In studies with repeat meas-
urements of indicators of adiposity, those who 
lose weight have BP levels that are, on average, 
similar to those who started with a healthier 
weight [77,78]. However, since both BMI and BP 
track from childhood to adulthood, it is hard to 
disentangle the length of overweight from any 
impact of current size [79]. Cohort effects might 
also be present, as secular increases in overweight 
and obesity have been accompanied by decreases 
in BP, raising the possibility that the strength 
of association between BMI and BP may vary 
by cohort [8]. As for BP, greater adiposity at 
any age is associated with more adverse lipids, 
glucose and insulin, and there is evidence that 
weight loss, including in childhood, results in 
improvements in lipid profiles [77]. An analysis 
of four cohorts followed from childhood to early 
midlife found that individuals who had been 
overweight or obese in childhood but were not 
obese as adults had risks of hypertension, abnor-
mal lipid profiles and increased carotid intima–
media thickness (cIMT) similar to those who 
had normal BMI consistently from childhood to 
adulthood [80]. Further analysis in one of these 
cohorts – the Cardiovascular Risk in Young 
Finns study – found a higher cumulative lifetime 
BMI score based on four measures from child-
hood through to early adulthood was associated 
with higher cIMT and higher SBP and glucose 
levels. Mendelian randomization using the FTO 
gene as the instrumental variable representing 
lifetime exposure to BMI supported a causal 
relationship between high cumulative BMI and 
these same outcomes [81]. A study using a larger 
and older sample and a genetic score comprising 
three single-nucleotide polymorphisms known 
to have the largest effects on BMI suggested a 
causal association with IHD [82]. However, such 
studies cannot assess the relative importance of 
childhood and adolescent BMI compared with 
adult BMI.
As well as early-life adiposity, linear growth 
has also been studied, since shorter adult height 
is associated with higher rates of CHD [83]. Adult 
height, and in particular adult leg length, can 
be considered as a biomarker of early-life envi-
ronmental factors reflecting prepubertal growth, 
having been related more strongly than trunk 
length to breastfeeding and higher-energy diets 
in early childhood and a more advantaged early-
life socioeconomic environment [84,85]. Greater 
adult height and leg length, but less so greater 
trunk length, have generally been related to 
lower BP, better lipid profiles and lower glucose 
[86–90]. In the Medical Research Council (MRC) 
National Survey of Health and Development 
(NSHD), shorter leg length was not only asso-
ciated with BP level, but also with faster age-
related increases in BP and pulse pressure dur-
ing midlife [91], thus suggesting that detrimental 
early-life influences on vascular structure and 
function may increase vulnerability to the effects 
of aging on the arterial tree. In the same study, 
it was also demonstrated that the relationship 
between a better lipid profile in adulthood and 
longer adult leg length was reflected in similar 
associations with taller height at 2 years of age 
[88], and a more recent study now suggests that 
short height in childhood is associated with 
adverse cIMT levels in early old age [92].
● ● Life course social inequalities
The socioeconomic inequalities in health within 
the western Industrialized countries of the 
world are well documented. SEP in childhood, 
as indicated by the father’s occupational social 
class, education, income or living conditions, 
has been shown to be associated with CHD 
in a multitude of studies [93,94] over and above 
the influence of education and adult SEP. The 
mechanisms underlying many of the life course 
SEP differences in health remain to be eluci-
dated, but are likely to include behavioral and 
psychosocial pathways, although several studies 
highlighted the importance of education as a 
mediator [95].
A systematic review found consistent evi-
dence that those from the most adverse SEP 
in adulthood had the highest mean BP and a Future Cardiol. (2015) 11(1) 108
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greater risk of hypertension, [96], but generally, 
no association has been observed between child-
hood SEP (i.e., parental SEP) and BP measured 
in childhood, adolescence or early adulthood 
[97]. By contrast, a number of cohort studies have 
found that those from a more disadvanatged 
childhood SEP have higher BP in adulthood, 
independent of adult SEP [62,98]. In the MRC 
NSHD, with repeat measurements of adult BP, 
there was evidence of an amplification of the 
adverse effect of low childhood SEP on adult BP 
[62]. Such amplification with age could explain 
why little or no association is found between 
childhood SEP and BP measured in childhood 
and early adulthood, but that an association 
between childhood SEP and adult BP has been 
found. Disadvantaged conditions in childhood 
have also been linked to more adverse lipid and 
glucose profiles in adulthood [99–101], although 
there is some variation in the findings, with 
own education being more important in some 
studies [102]. In a study attempting to disen-
tangle the types of life course SEP models of 
cardiometabolic risk factors, the lifetime accu-
mulation model was predominant in women 
and the childhood sensitive period model was 
  predominant in men [101].
Linking cardiometabolic trajectories to 
disease progression & outcomes
BP in adolescence/early adulthood is related 
to CHD and stroke mortality in follow-ups 
of cohorts of alumni and military conscripts 
[103,104]. In the Cardiovascular Risk in Young 
Finns study, SBP assessed between 12 and 
18 years of age was positively associated with 
cIMT assessed at 33–39 years of age, with a 
magnitude similar to that of the association 
with SBP in adulthood assessed at the same time 
as cIMT [105]. For LDL-C, the earlier measure 
was more strongly related to cIMT [105]. In a 
subsequent multicohort study, including the 
Cardiovascular Risk in Young Finns study as 
well as the Childhood Determinants of Adult 
Health Study, the Bogalusa Heart Study and the 
Muscatine Study, which investigated the impor-
tance of age at measurement of the risk factor, 
higher total cholesterol from 12 years of age and 
higher SBP from 6 years of age were associated 
with higher young adult cIMT [106]. Associations 
with these risk factors measured at younger ages 
(3 years of age for SBP and 3, 6 and 9 years of 
age for cholesterol) were weak or null, as were the 
associations between triglyceride levels measured 
at all ages from 3 to 18 years of age and cIMT. In 
the Bogalusa Heart Study, the cumulative burden 
of high SBP (as indicated by the area under the 
SBP curve) over a 23-year period of childhood 
and early adult life, as well as a measure of SBP 
in adolescence/early adulthood, was associated 
with left ventricular mass index [107]. Evidence 
in support of a causal association between CHD 
and cumulative SBP exposure comes from a 
Mendelian randomization study suggesting that 
single-nucleotide polymorphisms associated with 
lower SBP were related to a slower age-related 
rises in SBP and a considerably greater reduc-
tions in risk of CHD than has been found in 
observational studies [108].
Evidence is accumulating to suggest that the 
midlife rises in BP have implications for subse-
quent disease development. The Lifetime Risk 
Pooling Project found that participants who were 
consistently hypertensive over at least 10 years 
and those whose BP increased to the level of 
hypertension had particularly high cumulative 
lifetime risks of CHD, while those whose BP 
decreased to normal levels had an estimated 
risk similar to those with BPs that had always 
been in the normal range [109]. In the CARDIA 
study, in which five latent classes of BP change 
were defined, groups with trajectories that were 
elevated–stable and elevated–increasing had 
higher odds of having a high coronary artery 
calcification score than the comparison low–sta-
ble group [29]. In a UK study, adults belonging 
to the subgroup with more marked increases in 
midlife SBP and DBP were more likely to have 
undiagnosed angina according to the Rose ques-
tionnaire than other participants [28]. In the same 
study, greater midlife increases in SBP were asso-
ciated with poorer cardiac structure, including 
left ventricular function at 60–64 years of age 
[110]. Greater increases between 43 and 53 years 
of age were shown to be a stronger risk factor 
of higher left ventricular mass index than more 
recent BP increases between 53 and 60–64 years 
of age. Whether this finding represents a detri-
mental impact of the rate of increase during a 
particular sensitive period of adult life or whether 
there is a lag effect that is independent of age 
or is a result of reverse causality remains to be 
seen. Whatever the mechanism, the implication 
for practice is that the possibility of identifying 
those who are at risk of future disease accord-
ing to their rate of change in BP, rather than 
through a single measurement (with a threshold 
for hypertension), should be further investigated.109
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Conclusion
Evidence from this article shows that changes 
in CV and metabolic function start early in 
life, long before the manifestation of disease, 
and that the rate of change varies by age and 
at times of biological transitions, most notably 
during pregnancy. There is strong evidence that 
early-life risk factors are involved in the ini-
tiation of adverse functional change. Despite 
cohort studies of adults and children collect-
ing repeated measures of cardiometabolic risk 
factors, few have fully utilized these data and 
explored the influences driving change in the 
measures or how change is related to disease pro-
gression. Understanding how markers of cardio-
metabolic function change across life and the 
characteristics associated with deviation from 
what might be considered underlying ‘normal’ 
age-related change is key to fully understanding 
the life course epidemiology of these conditions, 
and for identifying means of preventing future 
disease.
Future perspective
We envisage a continued development of the life 
course approach in CVD prevention, as high-
lighted in current guidelines, with increased 
recognition of the importance of changes in 
risk factors throughout life, including during 
pregnancy in women. The initiation of preven-
tative measures to improve lifestyle at all stages 
of life in order to prevent CVD in later life is 
executive summAry
Life course epidemiology
  ●   Life course epidemiology provides a framework by which to study cardiovascular aging across the life course.
Life course trajectories of cardiometabolic function
  ●   Repeated measures of cardiometabolic risk factors in the same individuals across large periods of the life course are 
preferable to comparisons of cross-sectional data, which are subject to secular and cohort effects.
  ●   Four life course phases for systolic blood pressure have been identified: a rapid increase coinciding with peak 
adolescent growth; a more gentle increase in early adulthood; a midlife acceleration; and a deceleration or decline in 
late adulthood.
  ●   Longitudinal data on lipids and glucose trajectories are limited.
Life course transitions
  ●   Puberty, pregnancy and the menopause transition are times of rapid change in cardiometabolic risk factors.
  ●   Women’s reproductive health can be seen as a sentinel of chronic disease, and there is evidence that problems in 
pregnancy unmask underlying cardiovascular disease (CVD) risk.
Life course risk factors for CvD
  ●   There is a large body of evidence suggesting that the origins of CVD are in early life and in utero.
  ●   Prenatal and postnatal growth are associated with later CVD and cardiometabolic risk trajectories, but the precise 
mechanisms behind this are not yet fully understood.
  ●   Social inequalities in CVD risk are initiated in childhood.
Linking cardiometabolic trajectories to disease progression & outcomes
  ●   Evidence suggests that childhood measures of cardiometabolic health are at least as strongly associated with 
cardiovascular outcomes as adult measures and that cumulative exposure may be important.
  ●   Changes in blood pressure in midlife are increasingly being found to be associated with CVD progression and 
outcomes.
Conclusion
  ●   Understanding how markers of cardiometabolic function change across life and the characteristics associated with 
deviation from what might be considered underlying ‘normal’ age-related change is key to fully understanding the life 
course epidemiology of these conditions and for identifying means of preventing future disease.Future Cardiol. (2015) 11(1) 110
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thus important. We would hope that the evi-
dence suggesting that the early midlife rate of 
change in BP – and possibly in other measures of 
cardiometabolic risk – is related to CV risk will 
have been thoroughly investigated and potential 
interventions robustly tested. The evidence that 
occupational cohorts have milder rises in BP sug-
gests what is potentially modifiable, even in the 
western context. Rapid technological develop-
ments will mean that more detailed longitudi-
nal phenotypes of cardiometabolic function and 
new measures of subclinical disease progression 
in large samples will become increasingly feasible 
and provide methods of capturing continual and 
dynamic changes in ways that do not put too 
much of a burden on study participants. This will 
enable investigation, for example, of the impact 
of short-term as well as longer-term variations in 
measures such as BP on disease development. 
Similarly, developments in the field of epigenet-
ics have the potential to explain the biological 
mechanisms linking early life and later disease. 
The growing number of intercohort collabora-
tions will continue in order to both provide the 
statistical power for analyses and the replication 
of findings in different populations. Such col-
laborations will also allow for the increasing 
application of methods for establishing causal 
associations.
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